The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
"The interest from surgeons and patients for a minimally invasivealternative to the current knee replacement options on the market continues toexpand," said Dr. Jeff Felt, Chairman of Advanced Bio-Surfaces. "We haveincreased the number of training sites in the United States in an effort toaccommodate the number of interested surgeons. As the surgeon community learnsmore about the product and its minimal surgical approach, they understand theneed for the OrthoGlide implant as a viable option for some patients. Thegrowth is inspired by surgeons who want to be trained on a procedure that canbe positioned as an alternative to total knee replacement."
In addition to training and supporting the orthopedic surgeon communityinterested in the OrthoGlide implant, ABS is also involved in a clinicalstudy. This week, during the American College of Rheumatology's annualmeeting in Boston, MA, William Arnold, M.D. will present data from the studythat supports the OrthoGlide's clinical effectiveness. The presentation willbe held in Room 153 of the Boston Convention and Exhibit Center at 5:30 p.m.on Saturday, November 10th.
About Advanced Bio-Surfaces, Inc.
ABS is a privately held company dedicated to the development of innovativejoint restoration products. The company's first product, the OrthoGlide MedialKnee Implant, is intended for the treatment of patients with moderateosteoarthritis of the medial compartment. The company received 510(k)clearance to market from the U.S. Food and Drug Administration (FDA) and CEmark notification from its Notified Body, in February 2006. For additionalinformation contact ABS at 952.912.5400 or visit the website athttp://www.advbiosurf.com.
SOURCE Advanced Bio-Surfaces, Inc.
You May Also Like